Key points
- FY26 revenue up 3% to $203.9 million, 6% at constant currency
- EBIT down 10% to $16.0 million, up 21% at constant currency
- Total trophon unit placements increased 9% to 4,230 units
- CORIS System Controlled Market Release progressing well
- New on-market share buyback of up to $40 million planned for FY27
Full summary
Nanosonics Ltd, a global leader in infection prevention solutions, announced its financial results for the year ended 30 June 2026. The company reported revenue of $203.9 million, up 3% year-on-year, or 6% at constant currency. Total trophon unit placements increased by 9% to 4,230 units, with a 6% growth in the global cumulative installed base to 39,230 devices. The company launched new trophon models, trophon3 and trophon2 Plus, which saw accelerating adoption in the second half of the year. EBIT was $16.0 million, down 10% year-on-year, but up 21% at constant currency. The trophon-only EBIT was $50.6 million, up 5% year-on-year, or 16% at constant currency. The CORIS System Controlled Market Release is progressing well, with positive customer feedback, and commercial launch is planned throughout FY27. Nanosonics also announced a new on-market share buyback of up to $40 million in FY27.
Guidance
FY27 revenue guidance: $220m to $228m, 8% to 12% growth at constant currency
Outlook
Nanosonics expects continued revenue growth from trophon and initial CORIS revenues in FY27. Gross margin is expected to moderate due to tariffs and freight costs. Operational expenses are expected to increase with increased investment in CORIS.